When was Rainer Theraputics founded?

Rainer Theraputics was founded in 2010.

Where is Rainer Theraputics located?

Rainer Theraputics is located in San Leandro, United States .

Who is the current CEO of Rainer Theraputics?

Scott Myers is the current CEO of Rainer Theraputics.

How many employees does Rainer Theraputics have?

Rainer Theraputics has 12 employees as of Dec 31, 2019.

When was the latest funding round of Rainer Theraputics?

Rainer Theraputics's latest funding round was on Jul 16, 2019.

Where does Rainer Theraputics rank among its competitors?

Rainer Theraputics ranks 75 amongst 187 active competitors.

Who are the top competitors of Rainer Theraputics?

Rainer Theraputics' top competitors are Xilio Therapeutics, Zymeworks and Harpoon Therapeutics.

Rainer Theraputics - 2025 Company Profile, Funding & Competitors

Company Details

Rainer Therapeutics is focussed on developing monoclonal antibody therapies for bladder cancer & achondroplasia, a rare skeletal condition which causes dwarfism. Its lead candidate B-701, a human IgG1 MAb which targets FGFR3 (fibroblast growth factor receptor 3) and acts against FGFR3-positive tumors. The candidate is in phase-2 trials for 2nd line metastatic bladder cancer and is in pre-clinical trials for achondroplasia.

Website
Email ID: @rainierrx.com
Phone Number: +1

Key Metrics

Founded Year

2010

Location

San Leandro, United States

Stage

Deadpooled

Total Funding

in 6 rounds

Latest Funding Round

Investors

Sofinnova Investments & 6 more

Ranked

75^th among

Employee Count

as on Dec 31, 2019

Similar Companies

Xilio Therapeutics &

Legal entities associated with Rainer Theraputics

Rainer Theraputics is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Jun 07, 2010	-	206	622

Get your free copy of Rainer Theraputics's company profile

Rainer Theraputics has raised a total funding of $80M over 6 rounds. Its first funding round was on Jun 04, 2014.

Rainer Theraputics has 7 institutional investors including Sofinnova Investments, Ysios Capital and Sectoral.

Here is the list of recent funding rounds of Rainer Theraputics:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Jul 16, 2019	Undisclosed	Conventional Debt	2519743	4741161	-
Jul 16, 2019	$10M	Series B	2285778	1819602	-
Jan 30, 2019	Undisclosed	Conventional Debt	7826364	7082273	-

Access funding benchmarks and valuations. Sign up today!

View details of Rainer Theraputics's funding rounds and investors

Top competitors of Rainer Theraputics include Xilio Therapeutics, Zymeworks and Harpoon Therapeutics. Here is the list of Top 10 competitors of Rainer Theraputics, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Xilio Therapeutics 2016, Waltham (United States), Public	Developer of immunotherapies for the treatment of cancer	$233M	Atlas Venture, Bay City Capital听&补尘辫;听	68/100
2nd	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	Perceptive Advisors, Northleaf听&补尘辫;听	68/100
3rd	Harpoon Therapeutics 2015, Cambridge (United States), Acquired	Developer of T-cell antibodies against hematologic and solid tumor targets	$130M	Ridgeback Capital Management, New Leaf Venture Partners听&补尘辫;听	67/100
4th	Harbour BioMed 2016, Shanghai (China), Series C	Developer of antibody therapeutics in immunology and oncology disease	$313M	Orbimed, Atlas Venture听&补尘辫;听	67/100
5th	Ambrx 2003, San Diego (United States), Acquired	Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders	$346M	Versant Ventures, HBM Partners听&补尘辫;听	67/100
6th	Lassen Therapeutics 2019, San Diego (United States), Series B	Developer of therapeutics to treat cancer	$116M	Frazier Healthcare Partners, Alta Partners听&补尘辫;听	65/100
7th	UroGen Pharma 2004, Ra anana (Israel), Public	Developer of therapeutics to treat urothelial and specialty cancers	$7M	Great Point Partners, RA Capital Management听&补尘辫;听	65/100
8th	Leap Therapeutics 2011, Cambridge (United States), Public	Acquiring and developing novel Immuno-Oncology therapeutics	$24.7M	Perceptive Advisors, Healthcare Ventures听&补尘辫;听	64/100
9th	BioAtla 2007, San Diego (United States), Public	Developer of immunotherapies for cancer using active biologics platform	$162M	HBM Healthcare Investments, HTIF听&补尘辫;听	63/100
10th	Merus 2003, Utrecht (Netherlands), Public	Developer of antibody-based drugs for cancer treatment	$156M	Tekla Capital Management, Sofinnova Investments听&补尘辫;听	63/100
75th	2010, San Leandro (United States), Deadpooled	Developer of antibody based therapeutics for bladder cancer	$80M	Tekla Capital Management, Sofinnova Investments听&补尘辫;听	31/100